Wang Philip S, Patrick Amanda R, Dormuth Colin R, Avorn Jerry, Maclure Malcolm, Canning Claire F, Schneeweiss Sebastian
National Institute of Mental Health, Bethesda, MD 20892-9629, USA.
Psychiatr Serv. 2008 Apr;59(4):377-83. doi: 10.1176/ps.2008.59.4.377.
Antidepressant therapies are underused among older adults and could be further curtailed by patient cost-sharing requirements. The authors studied the effects of two sequential cost-sharing policies in a large, stable population of all British Columbia seniors: change from full prescription coverage to 10-25 dollars copayments (copay) in January 2002 and replacement with income-based deductibles and 25% coinsurance in May 2003.
PharmaNet data were used to calculate monthly dispensing of antidepressants (in imipramine-equivalent milligrams) among all British Columbia residents age 65 and older beginning January 1997 through December 2005. Monthly rates of starting and stopping antidepressants were calculated. Population-level patterns over time were plotted, and the effects of implementing cost-sharing policies on antidepressant use, initiation, and stopping were examined in segmented linear regression models.
Implementation of the copay policy was not associated with significant changes in level of antidepressant dispensing or the rate of dispensing growth. Subsequent implementation of the income-based deductible policy also did not lead to a significant change in dispensing level but led to a significant (p=.02) decrease in the rate of growth of antidepressant dispensing. The copay policy was associated with a significant (p=.01) drop in the frequency of antidepressant initiation among persons with depression. Income-based deductibles reduced the rate of increase in antidepressant initiation over time. Implementation of the copay and income-based deductible policies did not have significant effects on stopping rates.
Introducing new forms of medication cost sharing appears to have the potential to reduce some use and initiation of antidepressant therapy by seniors. The clinical consequences of such reduced use need to be clarified.
抗抑郁疗法在老年人中未得到充分利用,且患者的费用分担要求可能会进一步限制其使用。作者研究了在不列颠哥伦比亚省所有老年人这一庞大且稳定的人群中,两项相继实施的费用分担政策的影响:2002年1月从全额处方保险改为10至25美元的自付费用(共付额),并于2003年5月被基于收入的免赔额和25%的共保率所取代。
利用PharmaNet数据计算1997年1月至2005年12月期间不列颠哥伦比亚省65岁及以上居民每月抗抑郁药的配药量(以丙咪嗪等效毫克计)。计算开始和停止使用抗抑郁药的月发生率。绘制随时间变化的人群水平模式,并在分段线性回归模型中研究实施费用分担政策对抗抑郁药使用、起始和停药的影响。
共付政策的实施与抗抑郁药配药量水平或配药量增长率的显著变化无关。随后实施的基于收入的免赔额政策也未导致配药量水平的显著变化,但导致抗抑郁药配药量增长率显著下降(p = 0.02)。共付政策与抑郁症患者中抗抑郁药起始频率的显著下降(p = 0.01)相关。基于收入的免赔额随着时间的推移降低了抗抑郁药起始率的增加。共付政策和基于收入的免赔额政策的实施对停药率没有显著影响。
引入新的药物费用分担形式似乎有可能减少老年人对抗抑郁疗法的一些使用和起始。这种使用减少的临床后果需要进一步明确。